Cell Biomarkers in Lupus: Value for Diagnostic and Drug Therapy
A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Immunology".
Deadline for manuscript submissions: closed (31 May 2021) | Viewed by 25489
Special Issue Editors
Interests: autoimmunity; proteomics; cell signaling; CD38 function
Interests: autoimmunity; lupus; plasma cell differentiation; flow cytometry
Interests: autoimmunity; extracellular vesicles; cell signaling; CD38 function, microRNAs, psoriasis
Special Issue Information
Dear colleagues,
CD38 is a transmembrane glycoprotein with receptor-mediated signaling capabilities and is an enzyme that catalyzes nicotinamide adenine dinucleotide (NAD+) or nicotinamide adenine dinucleotide phosphate (NADP+) to produce molecules involved in Ca2+ messenger signaling. Moreover, in closed environments, CD38 in combination with other ectoenzymes is involved in the production of adenosine, an immunosuppressive nucleoside.Systemic lupus erythematosus (SLE) is an autoimmune disorder that is characterized by dysregulated immunity against the self, with abnormal production of autoantibodies that cause end-organ damage through immune complex deposition and chronic inflammation.In active SLE patients, the expression of CD38 in several immune cell types including T cells, plasma cells, regulatory B cells, and monocytes is significantly higher than in normal subjects. In contrast, SLE patients that develop anti-CD38 antibodies have a relatively well-controlled disease, suggesting that anti-CD38 therapy may be useful to deplete harmful effector T cells and autoantibody-producing plasma cells. However, in SLE the function of many of these cells seems to be intrinsically impaired, which poses the question of whether abnormal CD38 expression is rather a consequence of this abnormal function. This Special Issue of IJMS on the Cell biomarkers in Lupus: value for diagnostic and drug therapy welcomes contributions from basic and clinical scientists in the form of original research paper or reviews. We encourage papers starting from experimental observations and ending with a perspective related to the focus. The aim of the issue is to contribute to identify new cell biomarkers for early diagnosis of lupus or with prognostic and predictive value for therapy. In the long term, these studies may contribute to better select SLE patients that benefit for a given therapeutic approach. Studies with animal models of the disease are also encouraged.
Dr. Jaime Sancho
Dr. Esther C. Zumaquero
Dr. Mercedes Zubiaur
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- CD38
- systemic lupus erythematosus
- anti-CD38 mAb therapy
- experimental lupus models
- extrafollicular B cell activation pathway
- regulatory B and T cells
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.
